A total of 215 breast cancer patients were recruited from 17 institutions across the nation and randomly allocated to three cohorts in phase 2 trial, of which 71 participants received rHSA/G-CSF 1200 μg, 71 participants received rHSA/G-CSF 1500 μg, and 72 participants were treated with rhG-CSF 5 μg/kg, respectively (Fig. 1c). Here, CSF3 is linked to breast cancer.